Cargando…
Mechanism of action of lenalidomide in hematological malignancies
Immunomodulatory drugs lenalidomide and pomalidomide are synthetic compounds derived by modifying the chemical structure of thalidomide to improve its potency and reduce its side effects. Lenalidomide is a 4-amino-glutamyl analogue of thalidomide that lacks the neurologic side effects of sedation an...
Autores principales: | Kotla, Venumadhav, Goel, Swati, Nischal, Sangeeta, Heuck, Christoph, Vivek, Kumar, Das, Bhaskar, Verma, Amit |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736171/ https://www.ncbi.nlm.nih.gov/pubmed/19674465 http://dx.doi.org/10.1186/1756-8722-2-36 |
Ejemplares similares
-
Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies
por: McDaniel, Jessica M., et al.
Publicado: (2012) -
Expanding role of lenalidomide in hematologic malignancies
por: Ghosh, Nilanjan, et al.
Publicado: (2015) -
Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies
por: Blumel, Susan, et al.
Publicado: (2014) -
Novel insights into the mechanism of action of lenalidomide
por: Semeraro, Michaela, et al.
Publicado: (2014) -
Toward Therapeutic Drug Monitoring of Lenalidomide in Hematological Malignancy? Results of an Observational Study of the Exposure-Safety Relationship
por: Song, Zaiwei, et al.
Publicado: (2022)